Skip to main navigation
Menu
Focus & Strategy
Innovation & Pipeline
Disease Areas
Investors & Media
Contact
Focus & Strategy
President’s Letter
Leadership
Board of Directors
Innovation & Pipeline
Roluperidone (MIN-101)
Seltorexant (MIN-202)
MIN-301
Disease Areas
Schizophrenia
Insomnia and Mood Disorders
Parkinson’s Disease
Investors & Media
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Investor FAQs
Contact Us
Corporate Governance
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports and Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Focus & Strategy
President’s Letter
Leadership
Board of Directors
Innovation & Pipeline
Roluperidone (MIN-101)
Seltorexant (MIN-202)
MIN-301
Disease Areas
Schizophrenia
Insomnia and Mood Disorders
Parkinson’s Disease
Investors & Media
Press Releases
Events & Presentations
Corporate Governance
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports and Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact Us
Contact
Remy Luthringer, Ph.D.
Chief Executive Officer, Minerva Neurosciences
Bio
Chairman of the Board
Shareholder Tools
Printed Materials
Email Alerts
Downloads
RSS
Print
Share
RSS
